Dr. David Sans, FAARM, Ph.D., M.B.A., of New York, is a chemical engineer with a PhD in chemometric and artificial intelligence from Dr. Stusser's group at the ETH in Zurich and a Mount Sinai Board Certification in Cell Therapies. David has FINRA Series 7, 63, 15, and 55 licenses in Healthcare Investment Banking. David has over a decade of expertise in healthcare investment banking, providing a complete range of investment banking advisory services, including mergers and acquisitions, project financing, capital raising, and exceptional circumstances. Since 2008, David's customers have completed over 100 healthcare investment banking transactions, providing superior services to financial institutions, institutional investors in healthcare, and strategic partners. David developed the AI Pathology platform at Mount Sinai Hospital in New York in 2012 and sold it to Philips in 2021, among other things. David's IPOs include Unnovas Bio, which generated $600 million in value after its $10 million IPO in December 2020. David formerly worked at ImClone Systems as Vice President of Finance and Investment Strategy, reporting to the CEO and Board of Directors, and at Think Equity as Managing Director of Healthcare Banking. David began his career at Novartis as a Senior Medical Scientist during the introduction of Glove® (Imatinib) in Switzerland and at Pfizer as Director of Market Analytics during the launch of Rebid® (interferon beta-1a for MS) and Macugen®.